Results 181 to 190 of about 1,197,232 (253)

Patients 40 Years of Age or Older Have Comparable Return to Sport Rates, Reinjury Rates, and 2‐Year Patient‐Reported Outcomes After Medial or Lateral Meniscus Repair Compared With Patients Younger Than 40 Years of Age

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To compare patient‐reported outcomes, return to sport (RTS), and reinjury rates after meniscus repair in patients over and under the age of 40 years old. Methods Meniscus repair cases performed at a single tertiary care center between December 2010 and August 2021 with a minimum 2‐year follow‐up data were reviewed.
Alexander E. White, Tyler J. Uppstrom, Akshay K. Raghuram, Thun Itthipanichpong, Samarth V. Menta, Robert B. Baldwin, Shu‐Han Wang, Anil S. Ranawat   +7 more
wiley   +1 more source

Navigating the Unknown: A Sensemaking Inquiry into the Mental Health Experiences of First-Year University Students at a Regional University in Fiji. [PDF]

Behav Sci (Basel)
James KE, Tanzil SA.
europepmc   +1 more source

Gender Equity in Rheumatology Research: Global Analysis of Authors

Arthritis &Rheumatology, EarlyView.
Objective To investigate gender representation of authors in rheumatology research over the last decade. Methods Using metadata from original and review articles published between 2015 and 2024 in SCImago top two quartile (Q1, Q2) rheumatology journals, author gender was classified using two public databases.
Michael Girdwood, Jean W. Liew, Ida K. Haugen, Marcella F. Pazzinatto, Andrea M. Bruder, Nicola Dalbeth, Adam G. Culvenor, Tuhina Neogi   +7 more
wiley   +1 more source

Experiences of Pacific Peoples and their 'āiga/kāinga/kāiga/vuvale living with Parkinsons: A qualitative study. [PDF]

PLoS One
Silcock C, Lupe M, Makasini S, Hale L, Higgs C, Richards R.   +5 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Heart failure management systems in the Western Pacific Region: A rapid scoping review. [PDF]

Dialogues Health
Singh KN, Moloney A, Singh K, Kumar K, Gurung A.   +4 more
europepmc   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Corrigendum to "HPV vaccination policies and implementation for adolescents in low- and middle-income countries: a scoping review" [The Lancet Regional Health-Western Pacific Volume 72, July (2026), 101919]. [PDF]

Lancet Reg Health West Pac
Liu S, Wu D, Ye S, Xiao Y, Wu M, Chen S, Zhang X, Guo L, Zhang Q, Zhou Y, Wu X, Yang Q, Xiao R, Zhang J, Feng X, Wang J, Shi X, Zhang X, Xu J, Shao J, Tang S, Liu Q.   +21 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Population Genetics of <i>Seriola lalandi</i> Confirm Hemispheric Divergence and Reveal Genetic Structure in the Temperate Northern Pacific and Between Wild and Captive-Reared Fish. [PDF]

Ecol Evol
Martínez-Matus E, Aguilera F, Muñiz-Salazar R, Sepúlveda FA, González MT, Araneda-Tolosa C, Farfán C, Lafarga-De la Cruz F.   +7 more
europepmc   +1 more source